Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for hypoxic ischemic encephalopathy
IRCT20141209020258N154Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Melatonin with Placebo (2 arms). Primary endpoints: Neurological condition, Brain function and 2 more. Started Mar 2021; status: completed.
02
Drugs
melatonin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on IRCT20141209020258N154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N154.